Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock Holdings Cut by AH Capital Management L.L.C.

AH Capital Management L.L.C. reduced its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 97.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 108,568 shares of the company’s stock after selling 4,234,181 shares during the quarter. Ginkgo Bioworks comprises 0.1% of AH Capital Management L.L.C.’s portfolio, making the stock its 12th largest holding. AH Capital Management L.L.C. owned about 0.20% of Ginkgo Bioworks worth $885,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in shares of Ginkgo Bioworks by 9,440.6% in the first quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company’s stock valued at $37,000 after purchasing an additional 31,626 shares in the last quarter. Cetera Advisors LLC lifted its holdings in shares of Ginkgo Bioworks by 12.1% in the first quarter. Cetera Advisors LLC now owns 348,543 shares of the company’s stock valued at $404,000 after purchasing an additional 37,704 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Ginkgo Bioworks in the second quarter valued at $36,000. Wellington Wealth Strategies LLC. purchased a new stake in shares of Ginkgo Bioworks in the second quarter valued at $41,000. Finally, Forbes J M & Co. LLP purchased a new stake in shares of Ginkgo Bioworks in the third quarter valued at $1,019,000. 78.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on DNA shares. TD Cowen increased their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a report on Friday, September 20th. BTIG Research increased their price objective on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a report on Friday, August 23rd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $4.58.

Ginkgo Bioworks Stock Down 2.3 %

Shares of NYSE:DNA opened at $7.96 on Wednesday. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.26 and a 1 year high of $75.20. The stock’s fifty day moving average price is $7.88.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.